| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Anti-FcRL5 CAR-T Cell Therapy(Xuzhou Medical University) | Phase 2 Clinical | Xuzhou Medical University (Xzmu) | Multiple Myeloma | Details | |
| Cevostamab | RG-6160; BFCR-4350A; RO-7187797 | Phase 2 Clinical | Genentech Inc | Multiple Myeloma | Details |